SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Agile Therapeutics, Inc. (AGRX) , forward earnings yield 112.36%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($1.00, 33.8%).
- Forward P/E 0.9
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $1.00 (-33.8% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 31/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AGRX
Valuation Multiples
P/E (TTM)0.0
Forward P/E0.9
PEG Ratio0.01
Forward PEG0.01
P/B Ratio0.00
P/S Ratio0.17
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-6.71
Forward EPS (Est.)$1.70
Book Value / Share$0.00
Revenue / Share$9.08
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield112.36%
Dividend Yield0.00%
Analyst Target$1.00 (-33.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-2,822.01 |
$0.00 |
$-16.08M |
- |
| 2015 |
$-2,755.72 |
$0.00 |
$-30.34M |
- |
| 2016 |
$-2,033.18 |
$0.00 |
$-28.74M |
- |
| 2017 |
$-1,829.61 |
$0.00 |
$-28.3M |
- |
| 2018 |
$-1,152.82 |
$0.00 |
$-19.78M |
- |
| 2019 |
$-746.20 |
$0.00 |
$-18.44M |
- |
| 2020 |
$-1,291.56 |
$749K |
$-54.69M |
-7301.2% |
| 2021 |
$-63,115.50 |
$4.1M |
$-76.59M |
-1867.5% |
| 2022 |
$-58.79 |
$10.88M |
$-25.41M |
-233.5% |
| 2023 |
$-6.71 |
$19.59M |
$-14.47M |
-73.8% |
